The CH50 complement test measures whether the classical and terminal complement pathways can work together to destroy a target. It is a functional screening test, not a simple count of one protein. Clinicians use it when recurrent bacterial infections, invasive meningococcal disease, autoimmune illness, unexplained low complement levels, or complement-blocking treatment raises concern about the cascade’s overall activity.
A low CH50 result can come from an inherited component deficiency, active complement consumption, severe liver dysfunction, protein loss, a medication that blocks complement, or mishandling of the sample. The paired AH50 result is often the fastest way to narrow the location of a defect. A high CH50 is much less specific and may accompany inflammation or increased production of complement proteins. Because reference ranges and methods differ, the number should be interpreted with the laboratory’s own interval, C3 and C4 levels, symptoms, treatment timing, and specimen conditions.
- CH50 tests pathway function: It requires working C1 through C9 components needed for classical activation and membrane attack complex formation.
- Low CH50 with normal AH50 suggests an early classical-pathway problem: C1, C2, or C4 deficiency is a common screening pattern.
- Low CH50 and low AH50 suggest a shared defect or broad consumption: C3, C5–C9, medication effects, or poor sample handling may be involved.
- High CH50 is nonspecific: It may rise during inflammation but rarely identifies a disease on its own.
- The sample usually requires prompt processing and deep freezing: Delays can cause a falsely low result.
- No universal normal range exists: Units and cutoffs vary by assay and laboratory.
Table of Contents
- How CH50 Tests Complement Function
- Clinical Reasons for Ordering CH50
- Blood Draw and Specimen Handling
- What Low CH50 Can Mean
- Normal and High CH50 Results
- Using CH50 With AH50, C3, and C4
- Follow-Up Testing by Result Pattern
- Limitations, Treatment Effects, and Urgent Signs
How CH50 Tests Complement Function
CH50 stands for 50% hemolytic complement activity. In the traditional assay, patient serum is mixed with antibody-coated sheep red blood cells. If the classical complement pathway activates normally, the cascade progresses through C3 and C5 and forms the C5b-9 membrane attack complex, which lyses the cells. The laboratory determines how much serum is needed to produce 50% lysis.
Modern laboratories may use liposome-based, enzyme, or other automated methods rather than the original cell-lysis technique. The readout may be reported in units per milliliter, complement activity units, or another method-specific form. Regardless of method, the test asks whether the pathway has enough combined functional activity to reach the terminal step.
The classical pathway begins when C1 binds to immune complexes or other activating surfaces. C1 activates C4 and C2, producing a C3 convertase. Cleavage of C3 amplifies the response and helps build a C5 convertase. C5b then joins C6, C7, C8, and C9 to form the membrane attack complex.
Because every major step must work, a complete deficiency of one required component can make CH50 nearly undetectable. Partial deficiencies, active consumption, treatment, or technical damage may produce a less dramatic reduction.
CH50 does not directly measure the amount of each protein. A person may have a normal concentration of a component that does not function correctly. Conversely, a mildly reduced concentration may still permit measurable pathway activity. Functional testing and concentration testing answer related but different questions.
The alternative pathway is screened with the AH50 complement test. Ordering both gives a two-pathway map that can separate early classical defects from alternative-pathway defects and problems in the shared terminal cascade.
The word “total” can be confusing. CH50 does not add together the concentrations of all complement proteins. It tests the total functional capacity of one activation route and the shared terminal pathway. A person can have a normal CH50 while one component is mildly reduced, because the remaining amount is still sufficient for the assay. A person can also have a low CH50 even when measured protein concentrations appear normal if one component is dysfunctional.
CH50 also differs from activation markers. Soluble C5b-9, C3a, C4d, and related fragments indicate that complement has been activated in the body. CH50 measures how much functional reserve remains in the sample. High activation and preserved CH50 can coexist, and strong consumption can produce both high activation products and low functional activity. Choosing the right test depends on whether the clinician is asking about deficiency, consumption, or active pathway signaling.
Clinical Reasons for Ordering CH50
CH50 is commonly ordered when the pattern of illness suggests an inherited or acquired complement abnormality. It is not a routine “immune strength” test and is most useful when guided by a specific clinical question.
Possible indications include:
- Recurrent invasive infections with Neisseria meningitidis or Neisseria gonorrhoeae
- Severe or repeated infections caused by encapsulated bacteria
- A family history of complement deficiency
- Early-onset lupus-like disease or unusual immune-complex disease
- Persistently low C3 or C4 without a clear explanation
- Glomerulonephritis, vasculitis, cryoglobulinemia, or another condition associated with complement consumption
- Suspected deficiency of C1, C2, C4, C3, or a terminal component
- Monitoring of selected complement-inhibiting drugs
The infection pattern can provide clues. Early classical component deficiencies, especially C1q, C1r, C1s, C2, and C4 defects, are strongly associated with immune-complex autoimmunity and can also increase bacterial infection risk. C3 deficiency can cause severe recurrent infections with encapsulated organisms because C3 is central to opsonization. Deficiencies of C5 through C9 are especially linked to invasive Neisseria infection.
CH50 may be ordered in systemic lupus erythematosus, but its role differs from simple C3 and C4 monitoring. During active immune-complex disease, complement is consumed, so CH50 may fall. A low result can support the broader picture of activity, but it is not specific enough to diagnose a flare or determine treatment by itself.
In autoimmune monitoring, trends are more useful when the same assay is repeated under similar conditions and interpreted with symptoms, urine findings, kidney function, anti-dsDNA antibodies, C3, and C4. A patient can have clinically active disease with a normal CH50, and a persistently low result may reflect an inherited component deficiency rather than ongoing inflammation. A low baseline that never normalizes should therefore be interpreted differently from a value that drops during a flare and rises with recovery.
The test may also be requested after an unexpectedly low C4 or C3. CH50 helps show whether the concentration change has reduced functional pathway capacity. It does not, however, replace disease-specific evaluation. For example, low C4 in hereditary angioedema, cryoglobulinemia, or lupus arises through different mechanisms and must be paired with the appropriate clinical and laboratory studies.
The test may also be used before or during therapy with eculizumab, ravulizumab, or another complement inhibitor. These medicines intentionally block parts of the cascade, so a low CH50 can reflect expected pharmacologic suppression rather than disease. The laboratory number must be interpreted against the specific drug, dose timing, disease, and monitoring protocol.
CH50 is not the best first test for hereditary angioedema. That evaluation relies on C4, C1 inhibitor antigen, and C1 inhibitor function. It also does not replace quantitative immunoglobulins, vaccine-response studies, lymphocyte subsets, or neutrophil tests when a broader immunodeficiency is suspected.
Blood Draw and Specimen Handling
CH50 uses serum from a venous blood draw. Fasting is generally not necessary unless other tests ordered at the same time require it. The critical issue is preserving complement activity after collection.
Complement proteins can activate or deteriorate in the tube. Many reference laboratories require the specimen to clot for a specified period, separation of serum from cells within one or two hours, and immediate freezing at approximately −70°C. Refrigerated or room-temperature transport may be unacceptable. Repeated freeze-thaw cycles can also reduce activity.
Collection instructions vary by method. Some laboratories require a plain red-top tube and reject serum separator gel. Others accept different tubes if processing is prompt. The drawing site should use the performing laboratory’s exact instructions rather than assuming all complement tests are handled alike.
A falsely low CH50 should be suspected when:
- The result is unexpectedly near zero in a person without a compatible history
- The sample arrived unfrozen despite a frozen requirement
- Collection and processing times are unknown
- AH50 is also extremely low but C3 and C4 are normal and no drug effect is present
- A repeat sample processed correctly is normal
Before the draw, the patient should report complement inhibitors, recent plasma infusion, plasma exchange, major infection, surgery, severe inflammation, liver disease, and substantial kidney or intestinal protein loss. Fresh frozen plasma can temporarily supply missing complement proteins. Complement-blocking drugs can intentionally suppress the assay.
If the test is used for therapeutic monitoring, the ordering specialist may specify collection just before the next dose or at another standardized time. Random timing makes serial values difficult to compare.
Turnaround time can range from a few days to two weeks because many hospitals send the sample to a reference laboratory. The report should include the assay method, result, reference interval, and any specimen comments. Keeping the original report is useful because a bare number without its method and range may be impossible to compare later.
What Low CH50 Can Mean
A low CH50 means the sample did not complete the classical-to-terminal complement reaction at the expected level. It is a broad signal with several possible causes.
Inherited classical-pathway deficiency
When CH50 is low or absent and AH50 is normal, the defect is likely before C3 in the classical pathway. C1q, C1r, C1s, C2, or C4 may be missing or dysfunctional. Complete deficiencies often produce a very low or undetectable CH50.
C2 deficiency is among the more common inherited complement deficiencies in people of European ancestry. Some affected people remain well, while others develop recurrent bacterial infections, lupus-like autoimmunity, or vasculitis. C1q and complete C4 deficiencies have particularly strong associations with systemic lupus erythematosus.
C3 or terminal-component deficiency
If both CH50 and AH50 are low, a shared component is involved. C3 and C5 through C9 participate in both assays. Complete deficiency of one of these proteins can markedly reduce both functional tests.
Terminal deficiencies often present with recurrent meningococcal disease. C3 deficiency tends to cause broader susceptibility to severe pyogenic infections because C3 supports opsonization as well as terminal-pathway activation.
Complement consumption
Autoimmune, infectious, renal, and immune-complex disorders can activate and consume complement proteins. Examples include active lupus, some forms of glomerulonephritis, cryoglobulinemia, severe bacterial infection, and certain vasculitides.
Consumption often lowers several components together rather than producing the isolated pattern of one inherited absence. Measuring C3 and C4 helps show whether multiple proteins are being depleted.
Reduced synthesis or protein loss
Most complement proteins are produced in the liver. Advanced liver failure can reduce concentrations and function. Severe nephrotic syndrome or protein-losing enteropathy may remove complement proteins from the circulation. These conditions usually cause other laboratory abnormalities and clinical findings as well.
Medication effect
C5 inhibitors prevent membrane attack complex formation and can reduce CH50 to very low levels. Other complement-directed therapies may produce different patterns. A low result in a treated patient may show expected target engagement, inadequate drug exposure, or an assay-specific effect; the specialist must interpret it within the treatment protocol.
Preanalytical error
Improper temperature, delayed processing, prolonged storage, or repeated thawing can destroy functional activity. Technical error should be considered before diagnosing a rare inherited disorder from one isolated result.
Normal and High CH50 Results
A normal CH50 shows that the classical and terminal pathways had enough combined function under the assay conditions. It makes a complete deficiency of a required classical or terminal component unlikely. It does not exclude every complement disorder.
A person can still have:
- An alternative-pathway-specific deficiency with low AH50
- A lectin-pathway deficiency
- A partial component deficiency with enough residual function to remain within range
- An intermittent consumption process that was inactive at collection
- A regulatory defect that causes inappropriate activation without consistently lowering functional reserve
- A complement-mediated kidney or thrombotic disorder with normal screening assays
Normal CH50 also does not rule out antibody deficiency, cellular immunodeficiency, or phagocyte disorders. Recurrent infections should be evaluated according to the organism, site, age, severity, and broader immune history.
A high CH50 usually has limited specificity. Complement proteins can behave as acute-phase reactants, so increased production during inflammation, infection, obesity-related inflammation, or tissue injury may raise activity. Some laboratories do not emphasize high values because the assay was designed mainly to detect deficient function.
An elevated result does not prove that complement is damaging tissues, predict autoimmune disease, or show that the immune system is “overactive.” Complement activation products such as C3a, C5a, or soluble C5b-9 answer different questions from total functional capacity. A person may have strong activation in the body while still retaining a normal or high CH50 in the tube.
When high CH50 is isolated and the patient is clinically stable, clinicians usually interpret it alongside C-reactive protein, ESR, C3, C4, liver-produced proteins, and the reason the test was ordered. Repeating the test solely to chase a mild elevation is often unnecessary unless the broader clinical picture calls for it.
Using CH50 With AH50, C3, and C4
The most informative screening approach combines functional and concentration tests. CH50 shows classical-to-terminal function, AH50 shows alternative-to-terminal function, and C3/C4 concentrations help distinguish deficiency from consumption.
| CH50 | AH50 | Most likely pathway category | Examples to consider |
|---|---|---|---|
| Low or absent | Normal | Early classical pathway | C1, C2, or C4 deficiency; classical-pathway consumption |
| Normal | Low or absent | Alternative pathway | Factor B, factor D, properdin, or regulatory defect |
| Low or absent | Low or absent | Shared C3/terminal pathway or broad acquired problem | C3 or C5–C9 deficiency, consumption, drug effect, liver disease, poor handling |
| Normal | Normal | Major complete defects in tested pathways less likely | Consider lectin pathway, partial defects, other immune systems, or disease-specific studies |
C3 and C4 refine these patterns. Low C3 and low C4 together can reflect classical-pathway consumption, as in active immune-complex disease. Low C3 with relatively preserved C4 can point toward alternative-pathway activation, although this is not definitive. Normal C3 and C4 with absent CH50 and AH50 raise suspicion for a terminal-component defect or a technical problem.
The time course also matters. A genetic complete deficiency tends to produce a stable, reproducible pattern. Consumption may improve when infection or autoimmune activity settles. Medication suppression follows dosing and drug clearance. Serial results are most useful when the same laboratory method and similar collection conditions are used.
Follow-Up Testing by Result Pattern
An abnormal CH50 should lead to targeted confirmation rather than an indiscriminate panel.
- Verify collection and medication history. Confirm tube type, processing, freezing, complement inhibitors, and recent plasma exposure.
- Repeat CH50 with AH50. A new correctly handled specimen helps confirm the pathway pattern.
- Measure C3 and C4. These concentrations provide evidence of consumption and identify central component loss.
- Test pathway-specific components. Low CH50 with normal AH50 may lead to C1q, C1r, C1s, C2, or C4 testing.
- Assess shared terminal components. Low results in both assays may lead to C3, C5, C6, C7, C8, and C9 concentration or function studies.
- Consider complement regulators and activation markers. Factor H, factor I, soluble C5b-9, autoantibodies, and disease-specific studies may be relevant in kidney or thrombotic disorders.
- Use genetic testing when hereditary deficiency is likely. A molecular diagnosis can confirm the component involved and guide family screening.
- Evaluate other immune pathways. Immunoglobulins, vaccine antibody responses, lymphocyte subsets, or neutrophil studies may be needed when infections are not fully explained.
A confirmed early classical deficiency may prompt rheumatology as well as immunology follow-up because of autoimmune risk. A confirmed terminal deficiency calls for strong attention to meningococcal prevention, education, and rapid treatment of fever.
Vaccination commonly includes meningococcal ACWY and B vaccines, pneumococcal vaccines, and other age-appropriate immunizations. Some patients need antibiotic prophylaxis. The plan depends on the exact defect, prior infections, age, vaccine response, and specialist guidance.
Family members may benefit from functional or genetic testing. Many complement deficiencies are autosomal recessive, while properdin deficiency is X-linked and some regulatory defects follow other patterns. Genetic counseling can explain who should be tested and what carrier results mean.
A confirmed deficiency should be recorded clearly in the medical chart, including the exact component and functional pattern. This prevents future clinicians from dismissing a chronically low CH50 as sample error and helps emergency teams recognize infection risk quickly.
Limitations, Treatment Effects, and Urgent Signs
CH50 is a broad screening tool. It cannot identify one component, distinguish every inherited defect from acquired consumption, or prove that complement caused a patient’s symptoms. It is also highly vulnerable to specimen problems.
Common mistakes include:
- Interpreting CH50 without AH50
- Comparing numbers from laboratories that use different methods
- Calling a low value hereditary without repeating it
- Ignoring eculizumab, ravulizumab, or another complement inhibitor
- Assuming normal CH50 excludes all complement-mediated disease
- Treating a high value as a specific inflammatory diagnosis
- Forgetting that severe sepsis itself can consume complement
Patients receiving terminal complement inhibitors face a substantially increased risk of meningococcal disease even when vaccinated. CH50 monitoring does not replace vaccination, preventive antibiotics when prescribed, or urgent evaluation of symptoms.
Seek emergency care for sudden fever, severe headache, stiff neck, confusion, a rapidly spreading purple or red rash, severe weakness, fast breathing, or cold mottled skin. These can signal meningococcal infection or sepsis. People with a known terminal complement deficiency or complement-inhibitor treatment should follow their emergency plan immediately.
Prompt care is also needed for reduced urine output, new swelling, severe high blood pressure, unusual bruising, neurologic changes, or marked fatigue during an acute illness because these may accompany thrombotic microangiopathy or serious kidney disease.
For a stable person with an unexpected low CH50 and no acute symptoms, the appropriate next step is usually confirmation and pattern-based testing—not alarm. A correctly handled repeat sample, AH50, C3, C4, medication review, and clinical history can often separate technical loss, acquired consumption, treatment effect, and inherited deficiency.
References
- Immunodeficiency: Complement disorders 2024 (Review)
- Complement deficiencies and infections 2026 (Review)
- Complements and Their Role in Systemic Disorders 2024 (Review)
- Editorial: Current challenges in complement diagnostics 2023 (Review)
- Complement Testing – Complement Deficiency and Anticomplement Therapeutic Response Monitoring 2025 (Official Guidance)
- Complement Activity Total, (CH50) 2026 (Laboratory Test Guidance)
Disclaimer
CH50 results must be interpreted with the performing laboratory’s range, AH50, C3, C4, medications, symptoms, and specimen handling. This article is educational and does not diagnose complement deficiency, autoimmune activity, infection, or treatment response. Seek urgent care for symptoms of meningitis, sepsis, or sudden kidney and neurologic problems.
